ABECMA is the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
BRIDGEPORT, W.Va. — By the time Eric Tennant was diagnosed in 2023 with a rare cancer of the bile ducts, the disease had spread to…
Clinical trials can help researchers learn to better treat asthma – but they need diverse volunteers. Black and Latino children who have severe asthma, are prone to asthma attacks, and live in low-income urban neighborhoods are underrepresented in asthma treatment clinical trials, even though they are more likely than whites to face health inequities that …
The post Clinical Trial Identifies Potential Treatment for Asthma in Latino Children appeared first on Salud America.
For the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Nearly seven months after the fatal shooting of an insurance CEO in New York drew widespread attention to health insurers’ practice of denying or delaying…
Some big changes in 2022 and 2023 have set up the healthcare sector to advance screening for non-medical social needs in 2024 and beyond. This is great news as we work to address social determinants of health (SDoH), improve health outcomes, and reduce health disparities. But one key social need – transportation – isn’t getting …
The post As Social Need Screening Advances, Transportation Remains an Afterthought appeared first on Salud America.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
